MOUNTAIN VIEW, Calif., April 27, 2010 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the first quarter ended March 31, 2010 after the NASDAQ Market closes on Monday, May 3, 2010.
The company will conduct a conference call and an audio webcast at 1:30pm PT on the same day.
Date: May 3, 2010 Time: 1:30 PM PT
Listen via Internet: http://ir.vivus.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=42230&k=1762740D
Toll-free: 877-359-2916 International: 224-357-2386
A webcast replay will be available on the VIVUS website for 30 days.
About VIVUS
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE(R) (alprostadil), a first generation therapy for the treatment of erectile dysfunction, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.